New platform combines blood biomarkers, lifestyle data and AI to give people personalized insights on aging and chronic disease risk.
Imagine a single test that doesn’t just look at your blood but also interprets what it says about your health trajectory. That’s the idea behind the newly launched OneTest for Longevity by AI-powered diagnostic company 20/20 BioLabs. Available now for the public, the test is designed to provide a clear picture of how your body is handling long-term stress and inflammation, the hidden forces that quietly influence how we age [1].
Jonathan Cohen, CEO of 20/20 BioLabs, expressed excitement regarding the company’s partnership with DAISource, noting that it helps realize their vision for AI-driven health solutions. He explained that the collaboration has enabled them to leverage enterprise-grade AI to build a secure, scalable platform capable of making a significant impact on public health.
OneTest for Longevity is a tool that helps people understand patterns in their body before problems become visible, turning complicated science into practical guidance you can act on.
If you’ve ever heard the phrase “silent killer,” chronic inflammation fits that description perfectly. It creeps in slowly, sometimes unnoticed, and fuels conditions like diabetes, dementia and heart disease. The problem is, we rarely see it coming until a diagnosis changes everything.
OneTest measures specific inflammatory markers in your blood. These markers act like tiny signals, showing how your body responds to stress, diet and lifestyle choices. By pairing these signals with your reported eating habits and daily routines, the test can flag areas where small changes might make a big difference in long-term health.
Behind the scenes, the test uses IBM’s watsonx.ai technology. Think of it as a digital assistant reading thousands of scientific papers, then summarizing them in a way that makes sense for everyday life. Unlike some AI tools that spit out a number and leave you guessing, OneTest delivers “explainable” recommendations. You’ll get guidance on why certain foods or habits may be increasing inflammation and what adjustments might help. In short, the AI is a translator. It turns dense scientific research into practical, actionable insights you can understand.
The research powering OneTest is curated by Dr James R Hébert and his team at the University of South Carolina. Their Dietary Inflammatory Index scores foods based on how much they may increase or reduce inflammation. Using this framework, OneTest translates your blood results into personalized lifestyle guidance.
For example, if your markers suggest your body responds poorly to high-sugar diets, the test may recommend swapping sugary snacks for alternatives that are more anti-inflammatory. It’s about creating a roadmap for small changes that add up over time, ultimately influencing how long and how well you live.
The timing is notable. 20/20 BioLabs went public on Nasdaq on 19th February, under the ticker AIDX. The OneTest launch signals an early move into the growing longevity market, which increasingly prioritizes prevention over treatment.
In a sector often dominated by high-tech lab jargon, OneTest stands out for its human approach – combining biomarkers, lifestyle data and AI to give people a clearer understanding of their health today and tomorrow.
It’s important to note that OneTest is a laboratory-developed test, not FDA-approved, and is meant to inform, not diagnose. By translating complex data into actionable insights, 20/20 BioLabs is nudging longevity forward. For anyone curious about the intersection of science, technology and personal health, OneTest represents a step toward understanding your body before it tells you what’s wrong.
Photograph courtesy of 20/20 BioAge Labs
[1] https://s3.amazonaws.com/b2icontent.irpass.cc/3089/rl162738.pdf
